Table 1.
Patient# | Age | Gender | Race | Smoking | Stage‡ | Biopsy #1^ | Biopsy #1 Mutation | Biopsy #2^ | Biopsy #2 Mutation | Lines of therapy | EGFR TKI line | Best response to EGFR TKI | TTP on TKI(months) |
OS (months) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 (1) | 61 | M | White | Never | IV | Squamous (L1)† | exon 19 del | Adenosquamous (LLL lung) | exon 19 del | 3 | 2nd line | PR | 12.1 | 27.5 |
2 (2) | 71 | F | White | Never | IV | Squamous (RLL lung)† | exon 19 del | Adenocarcinoma (RLL lung) | exon 19 del | 2 | 1st line | Unavailable | 19.6 | 32.9+ |
3 (3) | 58 | F | White | Never | IV | Squamous (RUL lung) | exon 19 del | Adenosquamous (LLL lung)† | exon 19 del | 3 | 2nd line | SD | 23.6 | 32.2+ |
4 (4) | 45 | F | Hispanic | Never | IV | Squamous (sacrum) | exon 19 del | Adenocarcinoma (pleural fluid) | exon 19 del | 2 | 2nd line | Unavailable | Unavailable | 15.3 |
5 (5) | 46 | M | Asian | Never | IV | Squamous (R lung) | exon 19 del | Adenocarcinoma (SC LN) | exon 19 del | 1 | 1st line | PR | 5.0+ | 6.6+ |
6 (6) | 73 | M | White | Former (25 PY) | IV | Squamous (adrenal) | exon 19 del | Adenocarcinoma (SC LN) | insufficient | 2 | 3rd line | Unavailable | Unavailable | 29.8 |
7 (10) | 58 | M | Asian | Never | IV | Squamous (bronchus) | L858R | Squamous (T8) | insufficient | 1 | 1st line | PR | 1.9 | 2.5 |
8 (new) | 76 | M | White | Never | IV* | Squamous (R lung)† | insufficient | Adenocarcinoma (L lung) | exon 19 del | 1 | 1st line | PR | 5.3 | 5.3+ |
9 (new) | 68 | M | White | Never | IV | Squamous (L lung) | L858R | None | N/A | 4 | 4th line | PR | 2.8+ | 24.0+ |
10 (new) | 30 | F | Asian | Never | IV | Adenosquamous (R lung) | L858R | None | N/A | 2 | 1st line | PR | 8.4 | 10.9+ |
11 (new) | 50 | M | White | Never | IV | Adenosquamous (L lung) | exon 19 del | None | N/A | 1 | 1st line | PR | 9.2+ | 9.6+ |
In parentheses are corresponding patient IDs in reference (8).
Biopsy numbers are not chronologic: biopsy #1 represents the index case (EGFR mutant “SQCLC”)
Stage at the time of TKI treatment.
Prior Stage IIA treated with induction cisplatin + pemetrexed followed by LLL lobectomy
Acquired resistance biopsy
Abbreviations: SC LN supraclavicular lymph node, PR partial response, SD stable disease, PY pack years